KOSUNI KOREA
Korean News in English
Business

Is Samsung Bioepis' Keytruda Biosimilar Effective for Cancer Treatment?

Published October 6, 2026 · 2 views
Is Samsung Bioepis' Keytruda Biosimilar Effective for Cancer Treatment?

삼성바이오에피스 키트루다, 암 치료에 효과적인가요?

Clinical Equivalence of Samsung Bioepis' Biosimilar SB27 to Keytruda Proven

Samsung Bioepis has developed a biosimilar version of Keytruda (an immune-oncology drug) called 'SB27,' which has demonstrated equivalent efficacy in Phase 3 clinical trials compared to the original drug. This is a significant achievement amid intensified market competition following Keytruda's patent expiration.

On June 29, 2026, Samsung Bioepis announced that SB27 had proven equivalence in its Phase 3 clinical trial results. Given Keytruda's projected global market size of approximately 46 trillion won, this development has heightened expectations for Samsung Bioepis to play a leading role alongside competitor Celltrion.

Keytruda's patent will remain in effect until the end of 2025, creating a competitive landscape where biosimilar developers must finalize preparations before the patent expires. Samsung Bioepis completed its domestic product licensing application for SB27 on August 10, 2026, positioning it as the first biosimilar to Keytruda in the market and preparing for market leadership.

SB27 targets the same PD-L1 protein as Keytruda, replicating its immune-oncology mechanism. Clinical efficacy and safety data based on real-world patient information was released on May 18, 2026, providing healthcare professionals and patients with a more reliable picture of how SB27 performs in actual use. Samsung Bioepis introduced the name 'Adaloch' for this real-world data, which confirmed SB27's safety profile matched that of Keytruda.

With Keytruda's patent expiration driving rapid growth in the biosimilar market, Samsung Bioepis has demonstrated SB27's potential as a substitute for Keytruda. The company expects to maintain a leading role amid intensifying competition, particularly aiming to expand market share globally alongside Celltrion after 2027.

삼성바이오에피스 키트루다, 암 치료에 효과적인가요?

Clinical Research Process of Samsung Bioepis SB27 Biosimilar

Samsung Bioepis conducted multiple phases of clinical trials to develop SB27. On April 20, 2026, the results of Phase 3 trial SB16 were announced—a key milestone demonstrating early success in development. SB16 was the first clinical trial in the SB27 development process, confirming equivalent efficacy compared to Keytruda.

On May 6, 2026, PK (pharmacokinetic) results from a Phase 1 lung cancer trial were reported. PK confirmation is critical for verifying that a drug functions as expected within the body, supporting SB27's stability and safety profile. This demonstrated that SB27 follows the same metabolic pathway as Keytruda with comparable safety.

In the Phase 3 clinical trials, SB27 showed equivalent efficacy compared to the original Keytruda. This is a critical result proving biosimilars can deliver the same therapeutic outcomes as the reference drug, making it essential for product licensing applications. The Phase 3 trial was conducted across 10 countries with a total of 650 patients.

On May 18, 2026, Samsung Bioepis released 'Adaloch' real-world patient data on efficacy and safety based on actual usage experience. This data, collected from 300 lung cancer patients between May and October 2026, provided healthcare professionals and patients with a more reliable assessment of SB27's performance beyond clinical trial results.

Market Competition Landscape for Samsung Bioepis' Keytruda Biosimilar

Keytruda's global market size is estimated at approximately 46 trillion won, making Samsung Bioepis and Celltrion key competitors in this space. The patent expiration of Keytruda has spurred rapid growth in the biosimilar market, with Samsung Bioepis aiming to expand its market share through SB27.

SB27 is the first domestic biosimilar for Keytruda to complete a product licensing application in South Korea, marking an early-mover strategy that positions Samsung Bioepis ahead of competitors. The company aims to launch SB27 in the market by the first half of 2027.

With Keytruda's patent expiration driving rapid growth in the biosimilar market, Samsung Bioepis expects to play a leading role alongside Celltrion. Specifically, it plans to expand its global market share after 2027, competing with Celltrion for dominance in the Keytruda biosimilar space.

Confirming Efficacy and Safety of Samsung Bioepis' Keytruda Biosimilar

Multiple clinical trials were conducted to validate SB27's efficacy and safety. In Phase 3 trials, SB27 demonstrated equivalent effects compared to the original Keytruda, providing critical data that biosimilars can deliver identical therapeutic outcomes.

The 'Adaloch' real-world patient data released on May 18, 2026, reflects actual user experience and provides a more reliable picture of SB27's performance. This data is based on the usage results of 300 lung cancer patients and confirmed that SB27 has a safety profile similar to Keytruda.

Safety was validated in Phase 1 and Phase 3 trials, with PK results from the Phase 1 lung cancer trial confirming metabolic similarity to Keytruda. This demonstrates SB27 follows the same metabolic pathway as Keytruda with comparable safety, reinforcing its reliability as a biosimilar.

Key Information to Verify About Samsung Bioepis' Keytruda Biosimilar

The domestic product licensing application for SB27 was completed on August 10, 2026, marking an important step before market launch. Samsung Bioepis will undergo additional safety and efficacy verification through the product licensing review process.

Through SB27, Samsung Bioepis has demonstrated its potential as a Keytruda substitute, with expectations of playing a leading role alongside Celltrion in the competitive landscape. The company aims to launch SB27 in the market by the first half of 2027.

The real-world patient data on efficacy and safety was released on May 18, 2026, providing healthcare professionals with reliable information beyond clinical trial results. Patients are advised to consult healthcare providers for appropriate usage guidance.

Frequently Asked Questions

Does Samsung Bioepis' Keytruda biosimilar SB27 have the same effect as the original Keytruda?

SB27 demonstrated equivalent efficacy compared to Keytruda in Phase 3 clinical trials, so it is expected to provide similar therapeutic effects.

What is the market size for Keytruda biosimilars?

Keytruda's global market size is estimated at approximately 46 trillion won, which explains why Samsung Bioepis and Celltrion are emerging as key competitors in this space.

When was Samsung Bioepis' SB27 product licensing application completed?

South Korea's Samsung Bioepis completed the domestic product licensing application for SB27 on August 10, 2026.

The information in this article is based on reports from YH Medical News, Weekly Korea, Bio Spectator, Viewers, and Adaloch.

FAQ

Does Samsung Bioepis' Keytruda biosimilar SB27 have the same effect as the original Keytruda?

SB27 demonstrated equivalent efficacy compared to Keytruda in Phase 3 clinical trials, so it is expected to provide similar therapeutic effects.

What is the market size for Keytruda biosimilars?

Keytruda's global market size is estimated at approximately 46 trillion won, which explains why Samsung Bioepis and Celltrion are emerging as key competitors in this space.

When was Samsung Bioepis' SB27 product licensing application completed?

South Korea's Samsung Bioepis completed the domestic product licensing application for SB27 on August 10, 2026.

Korean Source

This article is an English localization of a Korean-language report from BlogScore. Original: 삼성바이오에피스 키트루다, 암 치료에 효과적인가요?